Biotech industry giant Mark Murcko this week offered a group of struggling Pittsburgh life science entrepreneurs a template for succeeding in a difficult market that included some simple words of advice: “Avoid stupid mistakes.”

“This is really hard. We all know this,” said Mr. Murcko, a 22-year veteran of Boston-based Vertex Pharmaceuticals, where he was chief technology officer and later served as principal or adviser to a number of biotech startups. “Science is just bloody difficult.”

Worse, “for the past few years, the market has been pretty ugly,” he told a few dozen entrepreneurs Tuesday at Bio Breakfast, a weekly networking event in South Oakland for the region’s life sciences community.

Mr. Murcko served as chief scientific officer at Vertex Pharmaceuticals and was a key contributor to the company’s Kalydeco medicine, which doctors have called a virtual cure for some forms of cystic fibrosis, a disabling and often fatal lung disease. He patented nine medicines, including ones for HIV and glaucoma.

Advertise with us

Since leaving Vertex, he has helped form and advise several biotech startups, including Dewpoint Therapeutics in Boston, where he serves as interim chief scientific officer.

Mr. Murcko, who has a doctorate degree in organic chemistry from Yale University, was a guest of Sharpsburg-based BioHybrid Solutions LLC, where he has served as a board member since 2022. He said he has been impressed by the company’s potential.

“It’s really looking very exciting,” he said.

BioHybrid Solutions is a Carnegie Mellon University spinout that was founded in 2016 by Alan Russell and fellow CMU scientists Kris Matyjaszewski and Antonina Simakova. The company, which is developing new ways of getting proteins into cells as medicines, has raised $2.9 million in capital and employs 18 people.

BioHybrid Solutions is a portfolio investment company of North Shore-based Innovation Works, a state-funded agency that financially supports startups.

Advertise with us

Success in starting a biotech company begins with the science underpinning the startup, which “has to be stellar” and “address a real medical need,” Mr. Murcko told the group. Lean management is also key along with a board that doesn’t micromanage.

“A board can completely screw up a company,” Mr. Murcko said.

Moreover, “avoiding stupid mistakes” will save startups from having to dig themselves out of “messes they’ve created,” he said. “And of course, there has to be enough money” from investors, who may prefer one city over another for a new company to set up operations, say, Silicon Valley over Pittsburgh.

Life science entrepreneurs have to clearly identify the patients who will be helped by their products and be aware that “manufacturing is way more complicated than you think it is,” Mr. Murcko said. Biotech startups would be smart to have their own in-house labs, which allow research flexibility, rather than relying on contract research organizations.

Developing new medicines and medical devices doesn’t happen quickly, Mr. Murcko said, so entrepreneurs and investors should think in terms of a 10-year timeframe.

Advertise with us

“We need to all understand the time horizon” and the “valley of death between labs and the market” when investment capital often lags, he said.

Despite market headwinds, BioHybrid Solutions President and CEO Jean Pineault said Pittsburgh has much to offer the biotech startup community.

“Pittsburgh has a lot of gems coming out of Carnegie Mellon and the University of Pittsburgh that the world needs to know about,” he said.

Kris B. Mamula: kmamula@post-gazette.com